CoPlex Therapeutics, LLC — Department of Health and Human Services STTR Phase II: NIA

Description

ABSTRACT Traditional mon therapeutictarget driven approaches to drug development for Alzheimer s diseaseADare becoming increasingly expensive and in many cases disappointingly unsuccessfulBased on preliminary in vitro and in vivo studies we have identified a novel small moleculemethyldimethyloxodihydrobenzo cnaphthyridinecarboxylateBNCthat significantly decreases neuroinflammation and production of Ain mouse models of AD pathology through Elkmediated transcriptional repression of presenilinbut not presenilinAlthough our preliminary data show BNCeffectively modulatesof the main pathologic features of AD without the adverse effects associated with current monotherapeuticsthere is a need for characterization of its basic pharmacology toxicity and for identification of the most efficacious treatment regimen in a well characterized mouse model of Adeposition and neuroinflammationX FAD miceIf successfulthe data obtained in this proposal will provide necessary pharmacology safety toxicology data to de risk the drug for potential corporate partners thus increasing the likelihood of successful commercialization